Answers are grounded in this paper and cite their sources.
// Xiang Ye 1,* , Yu Zhang 1,* , Qiping Xu 1 , Honghua Zheng 1 , Xiaoyan Wu 1 , Jinhua Qiu 1 , Zhou Zhang 2 , Wei Wang 3 , Yiming Shao 2 and Hui Qin Xing 1 1 Department of Pathology, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Basic Medicine, Medical College, Xiamen University, Xiamen, Fujian, China 2 State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China 3 Institute of Laboratory Animal Sciences of Chinese Academy of Medical Science, Beijing, China * These authors have contributed equally to this article Correspondence to: Huiqin Xing, email: // Keywords : AEG-1; EAAT-2; HIV-1 Tat; HIV-associated neurocognitive disorder; PI3-K Received : August 02, 2016 Accepted : January 23, 2017 Published : March 22, 2017 Abstract During HIV-associated neurocognitive disorder (HAND), decreasing in excitatory amino acid transporter 2 (EAAT-2) in astrocyte plasma membranes leads to elevated levels of extracellular glutamate and, in turn, neuronal apoptosis. We used immunohistochemistry, western blot, qRT-PCR, and RNA interference to elucidate the molecular mechanisms underlying the decreased EAAT-2 expression during HAND at the tissue and cellular levels. We used simian immunodeficiency virus-human immunodeficiency virus chimeric virus (SHIV)-infected macaques as an in vivo model of HAND. Our results show that EAAT-2 expression was decreased in the cerebral cortex, while AEG-1 expression was increased, and the expression levels of these proteins were negatively correlated. I n vitro analyses showed that HIV-1 Tat inhibited EAAT-2 expression by inducing overexpression of AEG-1. More specifically, HIV-1 Tat increased AEG-1 expression via the PI3-K signaling pathway, while increasing EAAT-2 inhibition by YinYan-1 (YY-1) via the NF-κB signaling pathway. These results warrant testing AEG-1 as a potential therapeutic target for treating HAND.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: